This activity is intended for infectious disease and HIV specialists engaged in the care of patients with HIV.
Though the proportion of heavily treatment-experienced patients with multidrug resistance is decreasing as new antiretroviral therapy (ART) regimens have increasingly high barriers to resistance, these patients with HIV often have only 1 opportunity remaining to address a failing regimen. Further, it is extremely challenging to simplify regimens for these patients. In the last few years, 3 new ART options for this population have been approved, and clinicians must remain up to date on how best to treat these complex cases. Drs. Onyema Ogbuagu and José Arribas discuss interpretation of resistance mutations, treatment options, and strategies for simplifying or switching salvage regimens in the case of virologic failure.
After completing this activity, the participant should be better able to:
- Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine
Director, HIV Clinical Trials Program
Section of Infectious Diseases
Yale School of Medicine
New Haven, Connecticut
José R. Arribas, MD
Director, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonóma University School of Medicine
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.
Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Onyema Ogbuagu, MBBCh, FACP, FIDSA: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare. Advisory Board: Janssen Pharmaceuticals, Inc.
José R. Arribas, MD: Consulting Fees, Advisory Board, Speakers Bureau: Aelix Therapeutics, Eli Lilly and Company, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., EMD Serono. Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare
The PACE planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Instructions to Receive Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 100% on the posttest, and complete the program evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
CME Questions – PACE Contact Information
For information about the accreditation of this program, please contact PACE https://partnersed.com/
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at firstname.lastname@example.org.